<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35114035</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1531-8257</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Movement disorders : official journal of the Movement Disorder Society</Title>
          <ISOAbbreviation>Mov Disord</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.</ArticleTitle>
        <Pagination>
          <StartPage>479</StartPage>
          <EndPage>489</EndPage>
          <MedlinePgn>479-489</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.28945</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Parkinson's disease (PD) causes a loss of neuromelanin-positive, noradrenergic neurons in the locus coeruleus (LC), which has been implicated in nonmotor dysfunction.</AbstractText>
          <AbstractText Label="OBJECTIVES">We used "neuromelanin sensitive" magnetic resonance imaging (MRI) to localize structural disintegration in the LC and its association with nonmotor dysfunction in PD.</AbstractText>
          <AbstractText Label="METHODS">A total of 42 patients with PD and 24 age-matched healthy volunteers underwent magnetization transfer weighted (MTw) MRI of the LC. The contrast-to-noise ratio of the MTw signal (CNR<sub>MTw</sub> ) was used as an index of structural LC integrity. We performed slicewise and voxelwise analyses to map spatial patterns of structural disintegration, complemented by principal component analysis (PCA). We also tested for correlations between regional CNR<sub>MTw</sub> and severity of nonmotor symptoms.</AbstractText>
          <AbstractText Label="RESULTS">Mean CNR<sub>MTw</sub> of the right LC was reduced in patients relative to controls. Voxelwise and slicewise analyses showed that the attenuation of CNR<sub>MTw</sub> was confined to the right mid-caudal LC and linked regional CNR<sub>MTw</sub> to nonmotor symptoms. CNR<sub>MTw</sub> attenuation in the left mid-caudal LC was associated with the orthostatic drop in systolic blood pressure, whereas CNR<sub>MTw</sub> attenuation in the caudal most portion of right LC correlated with apathy ratings. PCA identified a bilateral component that was more weakly expressed in patients. This component was characterized by a gradient in CNR<sub>MTw</sub> along the rostro-caudal and dorso-ventral axes of the nucleus. The individual expression score of this component reflected the overall severity of nonmotor symptoms.</AbstractText>
          <AbstractText Label="CONCLUSION">A spatially heterogeneous disintegration of LC in PD may determine the individual expression of specific nonmotor symptoms such as orthostatic dysregulation or apathy. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Madelung</LastName>
            <ForeName>Christopher F</ForeName>
            <Initials>CF</Initials>
            <Identifier Source="ORCID">0000-0002-0827-217X</Identifier>
            <AffiliationInfo>
              <Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meder</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fuglsang</LastName>
            <ForeName>Søren A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marques</LastName>
            <ForeName>Marta M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boer</LastName>
            <ForeName>Vincent O</ForeName>
            <Initials>VO</Initials>
            <AffiliationInfo>
              <Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Madsen</LastName>
            <ForeName>Kristoffer H</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Applied Mathematics and Computer Science, Technical University of Denmark, Kgs. Lyngby, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petersen</LastName>
            <ForeName>Esben T</ForeName>
            <Initials>ET</Initials>
            <AffiliationInfo>
              <Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hejl</LastName>
            <ForeName>Anne-Mette</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Løkkegaard</LastName>
            <ForeName>Annemette</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siebner</LastName>
            <ForeName>Hartwig R</ForeName>
            <Initials>HR</Initials>
            <AffiliationInfo>
              <Affiliation>Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mov Disord</MedlineTA>
        <NlmUniqueID>8610688</NlmUniqueID>
        <ISSNLinking>0885-3185</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D059331" MajorTopicYN="Y">Adrenergic Neurons</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">MRI</Keyword>
        <Keyword MajorTopicYN="Y">Parkinson's disease</Keyword>
        <Keyword MajorTopicYN="Y">locus coeruleus</Keyword>
        <Keyword MajorTopicYN="Y">non-motor</Keyword>
        <Keyword MajorTopicYN="Y">noradrenaline</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>17</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35114035</ArticleId>
        <ArticleId IdType="doi">10.1002/mds.28945</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017;18:435-450.</Citation>
        </Reference>
        <Reference>
          <Citation>Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006;16:46-54.</Citation>
        </Reference>
        <Reference>
          <Citation>den Brok MGHE, van Dalen JW, van Gool WA, van Charante EPM, de Bie RMA, Richard E. Apathy in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2015;30:759-769.</Citation>
        </Reference>
        <Reference>
          <Citation>Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaalund SS, Passamonti L, Allinson KSJ, et al. Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity. Acta Neuropathol Commun 2020;8:11</Citation>
        </Reference>
        <Reference>
          <Citation>Theofilas P, Ehrenberg AJ, Dunlop S, et al. Locus coeruleus volume and cell population changes during Alzheimer's disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement J Alzheimers Assoc 2017;13:236-246.</Citation>
        </Reference>
        <Reference>
          <Citation>Poe GR, Foote S, Eschenko O, et al. Locus coeruleus: a new look at the blue spot. Nat Rev Neurosci 2020;21:644-659.</Citation>
        </Reference>
        <Reference>
          <Citation>Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009;10:211-223.</Citation>
        </Reference>
        <Reference>
          <Citation>Braak H, del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.</Citation>
        </Reference>
        <Reference>
          <Citation>Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003;60:337-341.</Citation>
        </Reference>
        <Reference>
          <Citation>Ehrminger M, Latimier A, Pyatigorskaya N, et al. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 2016;139:1180-1188.</Citation>
        </Reference>
        <Reference>
          <Citation>García-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 2013;136:2120-2129.</Citation>
        </Reference>
        <Reference>
          <Citation>Isaias IU, Trujillo P, Summers P, et al. Neuromelanin imaging and dopaminergic loss in Parkinson's disease. Front Aging Neurosci 2016;8:196</Citation>
        </Reference>
        <Reference>
          <Citation>Li Y, Wang C, Wang J, et al. Mild cognitive impairment in de novo Parkinson's disease: a neuromelanin MRI study in locus coeruleus. Mov Disord 2019;34:884-892.</Citation>
        </Reference>
        <Reference>
          <Citation>Sommerauer M, Fedorova TD, Hansen AK, et al. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. Brain 2018;141:496-504.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J, Li Y, Huang Z, et al. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes. Eur J Neurol 2018;25:949-e73.</Citation>
        </Reference>
        <Reference>
          <Citation>Aston-Jones G, Ennis M, Pieribone VA, Nickell WT, Shipley MT. The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science 1986;234:734-737.</Citation>
        </Reference>
        <Reference>
          <Citation>Loughlin SE, Foote SL, Grzanna R. Efferent projections of nucleus locus coeruleus: morphologic subpopulations have different efferent targets. Neuroscience 1986;18:307-319.</Citation>
        </Reference>
        <Reference>
          <Citation>Mason ST, Fibiger HC. Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J Comp Neurol 1979;187:703-724.</Citation>
        </Reference>
        <Reference>
          <Citation>Castellanos G, Fernández-Seara MA, Lorenzo-Betancor O, et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov Disord 2015;30:945-952.</Citation>
        </Reference>
        <Reference>
          <Citation>Sasaki M. Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications. NeuroReport 2008;19:1649-1654.</Citation>
        </Reference>
        <Reference>
          <Citation>Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17:1215-1218.</Citation>
        </Reference>
        <Reference>
          <Citation>O'Callaghan C, Hezemans FH, Ye R, et al. Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease. Brain 2021;144(8):2513-2526.</Citation>
        </Reference>
        <Reference>
          <Citation>Keren NI, Taheri S, Vazey EM, et al. Histologic validation of locus coeruleus MRI contrast in post-mortem tissue. NeuroImage 2015;113:235-245.</Citation>
        </Reference>
        <Reference>
          <Citation>Priovoulos N, Jacobs HIL, Ivanov D, Uludag K, Verhey FRJ, Poser BA. High-resolution in vivo imaging of human locus coeruleus by magnetization transfer MRI at 3T and 7T. NeuroImage 2018;168:427-436.</Citation>
        </Reference>
        <Reference>
          <Citation>Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591-1601.</Citation>
        </Reference>
        <Reference>
          <Citation>Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.</Citation>
        </Reference>
        <Reference>
          <Citation>Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. Recent Dev Park Dis. 1987;2:153-163.</Citation>
        </Reference>
        <Reference>
          <Citation>Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017;264:1567-1582.</Citation>
        </Reference>
        <Reference>
          <Citation>Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.</Citation>
        </Reference>
        <Reference>
          <Citation>Drijgers RL, Dujardin K, Reijnders JSAM, Defebvre L, Leentjens AFG. Validation of diagnostic criteria for apathy in Parkinson's disease. Parkinsonism Relat Disord 2010;16:656-660.</Citation>
        </Reference>
        <Reference>
          <Citation>Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.</Citation>
        </Reference>
        <Reference>
          <Citation>Sockeel P, Dujardin K, Devos D, Denève C, Destée A, Defebvre L. The Lille Apathy Rating Scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:579-584.</Citation>
        </Reference>
        <Reference>
          <Citation>Ye R, Rua C, O'Callaghan C, et al. An in vivo probabilistic atlas of the human locus coeruleus at ultra-high field. NeuroImage 2021;225:117487</Citation>
        </Reference>
        <Reference>
          <Citation>Tustison NJ, Avants BB, Cook PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 2010;29:1310-1320.</Citation>
        </Reference>
        <Reference>
          <Citation>Fonov V, Evans AC, Botteron K, Almli CR, McKinstry RC, Collins DL. Unbiased average age-appropriate atlases for pediatric studies. NeuroImage 2011;54:313-327.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. NeuroImage 2009;44:83-98.</Citation>
        </Reference>
        <Reference>
          <Citation>Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP. In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology 2017;283:789-798.</Citation>
        </Reference>
        <Reference>
          <Citation>German DC, Manaye KF, White CL, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992;32:667-676.</Citation>
        </Reference>
        <Reference>
          <Citation>Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989;287:373-392.</Citation>
        </Reference>
        <Reference>
          <Citation>Giguère N, Burke Nanni S, Trudeau L-E. On cell loss and selective vulnerability of neuronal populations in Parkinson's disease. Front Neurol 2018;9:455</Citation>
        </Reference>
        <Reference>
          <Citation>Bertrand E, Lechowicz W, Szpak GM, Dymecki J. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol 1997;35:80-86.</Citation>
        </Reference>
        <Reference>
          <Citation>Doppler CEJ, Kinnerup MB, Brune C, et al. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. Brain 2021;144(9):2732-2744.</Citation>
        </Reference>
        <Reference>
          <Citation>Ye R, O'Callaghan C, Rua C, et al. Locus coeruleus integrity from 7T MRI relates to apathy and cognition in Parkinson's disease and progressive supranuclear palsy. medRxiv 2021. https://doi.org/10.1101/2021.04.19.21255762.</Citation>
        </Reference>
        <Reference>
          <Citation>German D, Walker B, Manaye K, Smith W, Woodward D, North A. The human locus coeruleus: computer reconstruction of cellular distribution. J Neurosci 1988;8:1776-1788.</Citation>
        </Reference>
        <Reference>
          <Citation>Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. Mov Disord 2014;29:1710-1719.</Citation>
        </Reference>
        <Reference>
          <Citation>Kelberman M, Keilholz S, Weinshenker D. What's that (blue) spot on my MRI? Multimodal neuroimaging of the locus Coeruleus in neurodegenerative disease. Front Neurosci 2020;14. https://doi.org/10.3389/fnins.2020.583421</Citation>
        </Reference>
        <Reference>
          <Citation>Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, de Deurwaerdere P, Miguelez C. The noradrenergic system in Parkinson's disease. Front Pharmacol 2020;11. https://doi.org/10.3389/fphar.2020.00435</Citation>
        </Reference>
        <Reference>
          <Citation>Mather M, Joo Yoo H, Clewett DV, et al. Higher locus coeruleus MRI contrast is associated with lower parasympathetic influence over heart rate variability. NeuroImage 2017;150:329-335.</Citation>
        </Reference>
        <Reference>
          <Citation>Elam M, Svensson TH, Thoren P. Differentiated cardiovascular afferent regulation of locus coeruleus neurons and sympathetic nerves. Brain Res 1985;358:77-84.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang X, Piñol RA, Byrne P, Mendelowitz D. Optogenetic stimulation of locus Ceruleus neurons augments inhibitory transmission to parasympathetic cardiac vagal neurons via activation of brainstem α1 and β1 receptors. J Neurosci 2014;34:6182-6189.</Citation>
        </Reference>
        <Reference>
          <Citation>Wood CS, Valentino RJ, Wood SK. Individual differences in the locus coeruleus-norepinephrine system: relevance to stress-induced cardiovascular vulnerability. Physiol Behav 2017;172:40-48.</Citation>
        </Reference>
        <Reference>
          <Citation>Braak H, Sastre M, Bohl JRE, de Vos RAI, del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol (Berl) 2007;113:421-429.</Citation>
        </Reference>
        <Reference>
          <Citation>Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003;18:890-897.</Citation>
        </Reference>
        <Reference>
          <Citation>Betts MJ, Cardenas-Blanco A, Kanowski M, et al. Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF Aβ levels. Alzheimers Dement 2019;11:281-285.</Citation>
        </Reference>
        <Reference>
          <Citation>Prasuhn J, Prasuhn M, Fellbrich A, et al. Association of locus coeruleus and substantia nigra pathology with cognitive and motor functions in patients with Parkinson disease. Neurology 2021;97:e1007-e1016.</Citation>
        </Reference>
        <Reference>
          <Citation>Trujillo P, Summers PE, Ferrari E, et al. Contrast mechanisms associated with neuromelanin-MRI. Magn Reson Med 2017;78:1790-1800.</Citation>
        </Reference>
        <Reference>
          <Citation>Trujillo P, Petersen KJ, Cronin MJ, et al. Quantitative magnetization transfer imaging of the human locus coeruleus. NeuroImage 2019;200:191-198.</Citation>
        </Reference>
        <Reference>
          <Citation>Cassidy CM, Zucca FA, Girgis RR, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci 2019;116:5108-5117.</Citation>
        </Reference>
        <Reference>
          <Citation>Mouton PR, Pakkenberg B, Gundersen HJG, Price DL. Absolute number and size of pigmented locus coeruleus neurons in young and aged individuals. J Chem Neuroanat 1994;7:185-190.</Citation>
        </Reference>
        <Reference>
          <Citation>Ohm TG, Busch C, Bohl J. Unbiased estimation of neuronal numbers in the human nucleus coeruleus during aging. Neurobiol Aging 1997;18:393-399.</Citation>
        </Reference>
        <Reference>
          <Citation>Betts MJ, Cardenas-Blanco A, Kanowski M, Jessen F, Düzel E. In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. NeuroImage 2017;163:150-159.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu KY, Acosta-Cabronero J, Cardenas-Blanco A, et al. In vivo visualization of age-related differences in the locus coeruleus. Neurobiol Aging 2019;74:101-111.</Citation>
        </Reference>
        <Reference>
          <Citation>Tona K-D, Keuken MC, de Rover M, et al. In vivo visualization of the locus coeruleus in humans: quantifying the test-retest reliability. Brain Struct Funct 2017;222(9):4203-4217.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
